Richmond Pharmacology is excited to attend the 2024 American HeartAssociation (AHA) Scientific Sessions in Philadelphia. This premier event incardiovascular science will bring together global leaders to present anddiscuss the latest innovations in cardiovascular research, prevention, andtreatment. The sessions will cover a wide range of topics, including basic,clinical, and population science.
To connect with our team during the event, please reach out to arrange ameeting.
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
